Intensive-Dose Tinzaparin in Hospitalized COVID-19 Patients: The INTERACT Study
입원한 COVID-19 환자의 집중 용량 Tinzaparin: INTERACT 연구
Observational Study
[키워드] Activation
Administered
Admission
adverse outcome
anticoagulation
bleeding event
clinical
clinical effectiveness
coagulation cascade
coronavirus
COVID-19
COVID-19 patient
CRP levels
current
D-dimer
D-dimer level
death
Deep venous thrombosis
diagnosed
discharge
dose
DVT
evaluate
favor
Greece
hospital
Hospitalized
hospitalized COVID-19 patient
hypercoagulability
increasing age
initiated
intermediate dose
Laboratory
low molecular weight
Low molecular weight heparins
median age
median treatment duration
men
moderate disease
Mortality
non-critically ill patient
Observational cohort study
occurred
oxygen saturation
participant
participated
Patient
pharmacological
Platelet
pro-inflammatory
progression
Prophylactic
prophylactic dose
Prophylaxis
receive
retrospective
SARS-CoV-2
severity
therapeutic
Thromboprophylaxis
thrombosis
thrombotic event
tinzaparin
tinzaparin.
Venous Thromboembolism
VTE
were recorded
WHO
with COVID-19
World Health Organization
[DOI] 10.3390/v14040767 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.3390/v14040767 PMC 바로가기 [Article Type] Observational Study